Hello, everybody. This is Matsui of Sysmex. Thank you very much for joining Sysmex financial results briefing meeting for the second quarter. Thank you indeed. Today, we will be covering the following. Page three. We will cover the first half financial results. Starting from this fiscal year, we have been working to review the business portfolio. We will be giving you the interim report. This is the positioning. This is not the final result. Plus, we will also explain this fiscal year's financial forecast for the full year. These are the main points we will be covering today. The key explanation today is going to be the review of the business portfolio.
Starting from April, the senior management gathered in the meeting and discussed about this topic. We also had intensive discussions in the offsite meeting, two nights and three days, among senior management and have conducted deep discussions. We have yet just been able to see the overall framework and not reached conclusions yet. Since I became president, I wanted to see the entire value chain of Sysmex. Therefore, research, development, and production, these areas which were rather distant from my background, I have been meeting and discussing with these value chain function members to understand what are the key points. I think I have been able to start understanding the key points. This has been my seven months. Next slide, please. Next. This is the first half numbers, which was already announced yesterday.
For net sales, U.S. and Brazil hematology instruments are now at the replacement timing. This thrust will continue for this fiscal year, in my view. The hematology instruments replacement rate in the U.S. is 99%, which means out of 100 units, only one will go to a competitor. All the rest will be renewed to our equipment. This is the situation continuing in this financial year. Americas is now leading and driving up the group-wide performance now. Last fiscal year, we struggled with China. We had quite a conservative view. This fiscal year is within our expectation. This is how things are proceeding. The insurance points are now being revised. Once they are decided, the outlook for China will become more clear, we think. Mr. Iizuka will explain about this more later.
For profits, the consolidated subsidiary goodwill was impaired, which was minus JPY 5.7 billion. We had this impairment loss, but with the sales increase, gross profit increased, and operating profit increased, all in all. As for cash, operating cash flow and free cash flow, both compared to last fiscal year, we improved a lot. We are now seeing revival in the ability to generate cash. Next slide, please. Taking this into consideration, this is our full year forecast. Basically, the second half numbers we set at the beginning of the year are maintained. On top of that, we added the first half actual results. This is the financial forecast for the full year. Within this, we had JPY 4.5 billion portfolio review operating expenses expected included, but this is also staying in the full year forecast.
This time, with the review of the business portfolio, there can be other operating profits that may be generated, which is also factored in, but they are not yet clearly visible. Depending on how things go, the numbers may slightly go up and down, but if there are changes, we will be announcing to you. Next slide, please. Now, the review of the business portfolio. Earlier, I touched upon the discussions amongst senior management, and after the discussions, we have defined core areas where we want to cherish going forward and where we want to focus investments in. There are four: hematology, hemostasis, urinalysis, and immunochemistry. Immunochemistry, we will not broaden globally, but we will narrow determined areas and narrow the parameters we want to roll out immunochemistry in the niche areas.
Underneath, we talk about development and the immunology or immunochemistry technology to measure proteins will become the platform for dementia. Therefore, we want to maintain immunology. For dementia, this is my personal view, but a lot is now visible about cancer treatment. Where will the human wisdom next go to? My personal view is to brain. One of the brain areas is Alzheimer's. There, we want to be in, and there, we want to secure a certain presence. There will be various new drugs to be launched going forward, and the diagnostics that will match the new drugs. When the clinicians think about whether a certain drug is appropriate for that patient, for the clinician to determine, we want to prepare a good lineup of biomarker testing reagents. This is going to become a very important factor to deal with dementia.
There are many manufacturers in the market, and we want to be able to create cutting-edge biomarkers and provide to the market. We want to have a broad-ranging biomarkers for dementia. This is where we want to grow. Starting from April, clinical chemistry has joined us, and hematology and clinical chemistry is, in a way, together, because clinical chemistry is also about screening. We want to cherish clinical chemistry. Then to move on to talk about life science. Sysmex has been in life science business, LS business, for a quarter of a century, but with the review of the business portfolio this time, we will not seek profitability on a standalone business basis, but within diagnostics will be one testing parameter that we want to have. That is gene analysis.
For life science, we have continued for the 25 years so far, and this has allowed us to have clinical development capabilities newly, and ability to put in into the treatment guideline, and have developed relationship with academic societies and built network with the global KOLs. This is what we have as the life science assets, and we will continue to succeed these assets and continue. In life science or genetic analysis, application and diagnostics are the areas we want to specialize on, we decided. Now, on medical business or medical robotics, we have formed a joint venture with Kawasaki Heavy Industries, a company called Medicaroid, and promoting this medical robotics business. Globally, we have now 120 instruments launched in the market. In Japan, more than 100 are under operation, and 60% of them are in university hospitals.
We have as much presence in the market, but we are not yet achieving profitability. For profitability at Sysmex, how are we going to improve? As Medicaroid, how are we going to improve? As Kawasaki Heavy, how to improve in terms of profitability? The three parties have started discussions. This cannot be determined by Sysmex alone. The related parties need to continue discussing going forward, and we need to accelerate our discussions. This MR business, what is going to be the direction? Within this fiscal year, we want to clarify our direction. Business-related subsidiaries will also be a scope of review this time. We have not been able to show you the conclusion yet, but we are now in the discussion stage with certain companies, and once decisions are made, we want to announce.
This time, following the review of our business portfolio, the research themes are also changing. We also have in overseas our RDC site, and their roles will be reviewed. Sysmex company's research division and development division's structure will also be refreshed, and themes will be reviewed as a part of the diagnostics business portfolio review. This will be a part of the review. This is what I am able to report to you about the review of the business portfolio today. Those of you here today, you may have expected something more radical, but it is something that requires some time, and there are many related parties and stakeholders. We need some more time, and we ask you to take a slightly longer-term approach, and we should be able to explain to you some time.
Good morning again. I am Iizuka. I would like to provide the overview again in a bit more detail. That said, leaving out what overlaps with what Matsui has already said and keep it as simple as possible. This would be, yes, this slide. This is precisely what Matsui was describing, so I will not go into too much of a detail. As you know, for China is still affecting us, but other regions centered around the U.S. are very strong overall. SG&A, and I will be talking about that later, are being appropriately controlled is what we think, and I will touch on few other key points. Foreign exchange is also positive. So overall, we have turned to growth in both sales and profit. The next slide. This is the results by business and field. Hematology is the largest for us and driving growth.
Sales increased by JPY 40.2 billion. When we exclude China and also the effect of the foreign exchange, hematology sales rose by 15.3%. Hemostasis declined in yen terms, but is heavily affected by China, as you already know. So if we exclude the effects of China and FX, grew by 22.8% even for hemostasis. Europe and U.S. are now picking up, and I believe things are progressing well overall. Also, although in absolute terms not very large, we have FCM, clinical chemistry, and immunoassay. They are all basically growing. Next slide, please. This is now by destination and product. If we focus on the products, instruments, and this is repeating myself, centering around the Americas, including EMEA, grew. So excluding FX, instruments did grow by 8.3%, especially in the Americas. North America and Latin America, including Brazil, were very strong.
On a local currency basis, we have seen growth by 16.5% year-on-year. China is still affected by the healthcare cost containment policy. Sales fell 22.4% in local currency, but this is within what we had anticipated. It is within our original plan. Instruments are growing nicely, so we expect the related reagents and service sales to follow. Slides for each destination, which follow this one, speak for themselves. Let me add a few points on China. If you could skip to page 14.
For China, since last fiscal year, healthcare cost containment policies and distributor inventory adjustments are continuing, and affected by these, result was minus 22.4% year-on-year. Local currency basis, distributor inventory adjustment wise, from Sysmex at sales to distributor sales is declining, but from the distributor side to the end user and installation at the users, in hematology and hemostasis, the number of units are going up. Reagents wise, the principle of minimal necessity has been affecting us, but with more instruments being installed, there may be a possibility of a moderate recovery. Next slide, please. We are showing you this slide every quarter, and this is the update. As you see, for the second quarter alone, minus 14.6% year-on-year, therefore within expectation.
For the second half outlook, from the second half of 2Q last year, we have been affected by the principle of minimal necessity, but for this policy, we have run its course. Distributor inventory adjustment we think may be prolonged, and testing price revisions. With these, we expect minus 10% year-on-year in the second half. No change from the initial forecast, but as shown on the next slide. The testing price revisions are ongoing, but compared to what we initially anticipated, the movement seems to be a bit slower. As you are aware, it is not just about pricing decline, but although moderate, there are some price increases being proposed as well. We need to more carefully monitor the progress. The six pilot provinces have announced their proposed revised prices, but still yet at the public consultation stage.
Other provinces also will be coming up with the prices, and we do not yet know whether these prices will be the fixed prices. Because other provinces are looking at these price proposals by the six pilot provinces, the full pricing results will be coming up later. The expectation now is to maintain the initial forecast. If you can move further to the operating profit, a change page 19. As you can see, JPY 10.18 billion increase in gross profit due to higher sales, and also absence of the prior year impact of inventory revaluation, plus JPY 1.75 billion. These are the two positive factors. On the other hand, for the cost of sales ratio, as I have touched upon earlier, the instrument sales is very strong, resulting in product mix impact. Plus, service costs and logistics costs are increasing.
Continuously with energy cost increases and inflation are affecting negatively. In total, 2.4 percentage point deterioration in cost of sales ratio. SG&A and R&D expenses, with the expansion in business, the amounts are increasing somewhat, but overall are controlled appropriately, we think. Last week, as we have informed you, in the clinical chemistry business, we booked impairment loss of minus JPY 5.7 billion. At the time of the first quarter, we explained that potential losses related to contractual obligations for purchased products. We are recognizing, which is JPY 1.7 billion, JPY 8.62 billion expenses, then with foreign exchange impact, JPY 33 billion operating profit. Next page, please. Next is the reasons for differences between planned and actual first half operating profit. In particular, the big part is SG&A and R&D expenses optimization, plus JPY 7.4 billion. We have reviewed the business portfolio.
This accompanied reviewing of the investments into business, also review of the R&D themes and the technology themes we will be studying. Looking at these results, we have strictly controlled our spending. This time in the first half, we did not include the JPY 4.5 billion for portfolio review expense. This had actually been included, but was not incurred, but still included in the full-year forecast. It is a matter of timing deferral to the second half. Next slide, please. Balance sheet. Here, as you are aware, for assets, long-term borrowings, plus, as Mr. Matsui said, operating cash flow have been increasing very strongly. Therefore, cash and cash equivalents increased. On the other hand, for equity, with share buybacks, equity came down. Next slide, please. Cash flows. As you are aware, free cash flow increased at JPY 34 billion, especially due to sales growth.
This is the foremost driver. Partially, the amount of tax payment came down, which also contributed. From here onwards, I will briefly cover progress against the strategic themes under the MTP. In order to achieve the MTP goals, we are advancing all four items in the light blue boxes together all at once, strengthening the competitiveness of the diagnostic business, promoting medical DX and data use, value chain transformation, and the financial and capital strategies all in a go. We will be raising profitability levels of all core areas and also reallocate capital to the next growth areas. So this will link us to enhancing of the mid-to-long-term corporate value. As stated, this is not merely downsizing or business consolidation. We are conducting this review to raise mid-to-long-term corporate value. Moving on to the next slide. The review scope covers all business areas and R&D.
We will use the two axes to review all projects for investment. One, quantitative, such as profitability, and qualitative, such as strategic importance. We defined these axes for evaluation, and we are reviewing businesses and the R&D portfolio against them. Now, which should identify the four categories, as you can see below the arrow in the middle of the page. Areas to refine strategy, areas to develop, areas where we will redefine the business approach, and areas to review strategically. So we are examining each. The next slide actually allows along the profitability and market growth axes show where we are in terms of each business, where they are positioned currently, and which direction we believe these businesses will move into. The areas of our strength, such as hematology, we will further raise or continue to raise quantitative advantage.
For areas of development, such as flow cytometry, clinical chemistry, and neurology.
Of course, we will be investing, but with discipline to pursue further growth. The next two slides give the current assessment, current recognition of ours, and the future direction for each area. I am not able to provide the details for each one. It is as you can see and read. For hematology, as already mentioned, we will reassess next-generation products planned for launch this fiscal year or during the midterm plan horizon, AI and data use, and competition in emerging markets. Those areas will be reassessed. Especially for AI and data use, I would like to provide further information using slides later. Moving further along. This is the life sciences field. As was mentioned by Matsui earlier, life science could mean many things to many people. For us, it mainly means genetic analysis for single or specific genes and also more comprehensive gene analysis.
There are different ways of addressing this. Since we established the Central Research Laboratories in 2000, we have pursued the life sciences field more broadly, which include exploratory technologies and working towards commercialization. One big difference then compared to now is the more leveraging of AI. Back then, we did not have that capability, or that did not exist. We now have this new possibility of using artificial intelligence, and so we feel that we should review how we approach life sciences and how we assess the potential. That was the starting point, and that was what Matsui was describing. From my standpoint, the key is people and talent. After running the business for many years, we have a real asset in talent who can create from 0 -1 and from 1 -1 0. By making most of them, we will shift resources to extending our core strength.
Also, we have already talked about medical robotics, so I will skip that because Matsui has already provided information. Again, today's content may fall a little short perhaps of your expectations that we are providing, but we are progressing steadily with the portfolio review. When it becomes possible for us to discuss specific cases, we intend to disclose and explain them promptly. Thank you.
Moving on to the next slide, which is about capital allocation. If you look at the bar chart at the top left, as you can see, over the past 10 years, where have we been investing in? In core areas, we invested more than 40%. This fiscal year, we will raise to 60%. Further, in the final year of the MTP, we want to invest over 70%. We have reconsidered the allocation of resources to invest heavily in the core areas. To repeat, this is not just about business, but also inclusive of R&D. For the R&D review, as you are aware, our base is in Kobe, but we also have global R&D centers, and the global R&D centers are also very important.
For example, the data-driven AI and usage of data in this regard, new research activities and new development activities are very important for global rollout. As of now, so far, the assets held by global R&D and the know-hows held by global R&D, we will be reviewing all over again to shift into new areas. It may be possible that we execute reduction in the headcount. Next page, please. Financial impact and disclosure policy. As I mentioned earlier, in the first half, we expected one-time expense of JPY 4.5 billion for review, and this is deferred to the second half. On the other hand, business-related subsidiaries, we are reviewing and discussing possible sales. This is also expected, but for specifics, allow me to repeat to say that once they are final, we will be disclosing.
By solidly moving ahead with these efforts, we intend to surely improve ROIC and free cash flow. Please move on to slide page 32. Medical DX initiatives. This is cross-horizontal and very important theme for us. In the middle, you can see early warning and triage systems, laboratory efficiency services, and infectious disease surveillance systems. These are the three strategic pillars. We want to connect the test results to the new treatment activities and enhancements. A part of the effort is our announcement two days ago at 7:00 P.M., joint venture with Hologen company. Our company's hematology and combining with the AI technology. Hematology testing will be able to discover early or create clinical activities and accelerate clinical activities. This is what we aim. The next slide shows that in the context of screening tests with AI and digital, we have two approaches.
The left-hand side, one is data-driven, from large-scale data to explore associations with disease and conditions. The other is, to the right, theme-driven, from the disease-centric approach, deep dive into clinical challenges and disease hypothesis. Both sides will continue to circulate together to create clinical value. If only on one side, will take more time, and if just on one other side, to be able to develop evidence, not sufficient. Therefore, we are taking approach, taking two perspectives. Next slide, please. Initiatives to improve profitability. This is a very important theme in the MTP, and the first half actual example is shown at the bottom. That is especially in this first half EMEA region. In this region, some of the selected products, actually main products, operation, by using digitalization assets we reviewed.
As a result, lead time was shortened by 15 days and inventory came down 10%. This is not for all the inventory in EMEA, but just for the selected products we have been able to achieve as much. We are now broadening to other products in EMEA and also broadening to other regions such as the Americas and Asia Pacific. We are rolling out further and more broadly. These are very basic activities, but over the three-year midterm plan period, we want to securely result in achievements.
Now finally, although the time is quite limited and I'll be spending shorter time on these pages, if you could please move to slide 36, full-year forecast. Here again, this is as announced. Net sales are at JPY 550 billion and operating profit JPY 68.5 billion. Key indicators such as ROE is at 8.0%, and ROIC of 8.5% according to our plan. On the next slide, we are showing changes, the factors which led to the changes in sales forecast. As Matsui already alluded to, we reflected the second half or first half upside in the latest forecast, but kept the second half at the original plan. If we see details by destination, for example, we see Japan's medical robot business being a bit weak, so we lowered that. On the whole, in the second half of the year, the forecast remains unchanged.
Next slide, this is for reference, sales by field and destination. The next slide shows the dividend forecast, which is unchanged from the beginning of the fiscal year. That concludes my presentation. Thank you.